Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012:2012:103763.
doi: 10.1155/2012/103763. Epub 2012 Mar 5.

Physiologically based pharmacokinetic modeling in pediatric drug development: a clinician's request for a more integrated approach

Karel Allegaert, Anne Smits, Johannes N van den Anker
Comment

Physiologically based pharmacokinetic modeling in pediatric drug development: a clinician's request for a more integrated approach

Karel Allegaert et al. J Biomed Biotechnol. 2012.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Integration of in vivo datasets analyzed by mechanism-based and PBPK predictive models results in a switch from “explorative, hypothesis-driven” to “confirmative” approach in the field of developmental physiology. This is illustrated for renal drug clearance in neonates, which reflects glomerular filtration rate (e.g., aminoglycosides) or a more complex pattern of known (glomerular filtration rate, protein binding) and still unknown (renal tubular transport ontogeny) (e.g., cefazolin) maturational processes.
See this image and copyright information in PMC

Comment on

References

    1. Khalil F, Läer S. Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development. Journal of Biomedicine and Biotechnology. 2011;2011:13 pages. Article ID 907461. - PMC - PubMed
    1. De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CAJ. The role of population PK-PD modelling in paediatric clinical research. European Journal of Clinical Pharmacology. 2011;67(supplement 1):S5–S16. - PMC - PubMed
    1. Läer S, Barrett JS, Meibohm B. The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. Journal of Clinical Pharmacology. 2009;49(8):889–904. - PubMed
    1. Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clinical Pharmacokinetics. 2006;45(11):1077–1097. - PubMed
    1. Johnson TN, Rostami-Hodjegan A. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatric Anaesthesia. 2011;21(3):291–301. - PubMed

LinkOut - more resources